
PharmaSGP Holding SE
PSG | F
Overview
Corporate Details
- ISIN(s):
- DE000A2P4LJ5
- LEI:
- 3912005CZ12PVVCIPT91
- Country:
- Germany
- Address:
- Lochhamer Schlag 1, 82166 Gräfelfing
- Website:
- https://pharmasgp.com/english/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
harmaSGP is a pharmaceutical company with a broad portfolio of leading, over-the-counter (OTC) drugs and other healthcare products. Our drugs are based on natural pharmaceutical active ingredients with documented efficacy and have virtually no known side effects. With our pharmacy-exclusive products, we have trusted brands in many relevant chronic indications that are leaders in their respective categories. The herbal-medicine Baldriparan®, is the leading OTC brand in Germany for natural valerian sleep aids. With the brands RubaXX® for rheumatic pain and Restaxil® for neuralgic pain (nerve pain), we are also the market leader for systemic, chemical-free OTC pain relievers. In addition, the products against sexual weakness, which are marketed under the brands DESEO® and NERADIN®, are the leading chemical-free products in their category in Germany. Since the launch of the first product from the current portfolio in Germany in 2012, we have successfully exported our business.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2025-06-11 11:15 |
Directors' Dealings
PharmaSGP Holding SE: FUTRUE GmbH, Interest-sustaining purchase order for up to…
|
English | 6.6 KB | |
2025-06-10 08:42 |
Delisting Announcement
PharmaSGP Holding SE: Conclusion of a delisting agreement and announcement of a…
|
English | 13.5 KB | |
2025-05-28 00:00 |
Regulatory News Service
Q1 statement / Q1 financial report 2025
|
English | 517.8 KB | |
2025-05-19 15:01 |
Directors' Dealings
PharmaSGP Holding SE: FUTRUE GmbH, buy
|
English | 6.0 KB | |
2025-05-16 07:30 |
Regulatory News Service
PharmaSGP continues its growth course in 2025
|
English | 15.9 KB | |
2025-05-14 15:05 |
Regulatory News Service
PharmaSGP Holding SE: Bekanntmachung der Einberufung zur Hauptversammlung am 25…
|
German | 127.8 KB | |
2025-05-09 11:00 |
Regulatory News Service
|
English | 12.1 KB | |
2025-04-30 00:00 |
Takeover Announcement Report
Annual financial report 2024
|
English | 22.7 MB | |
2025-04-23 14:30 |
Regulatory News Service
|
English | 4.4 KB | |
2025-04-15 07:30 |
Regulatory News Service
PharmaSGP with significant increase in revenues and EBITDA in 2024
|
English | 16.7 KB | |
2024-11-29 00:00 |
Quarterly Report
Q3 statement / Q3 financial report 2024
|
English | 517.2 KB | |
2024-11-28 00:00 |
Quarterly Report
Q3 statement / Q3 financial report 2024
|
English | 517.2 KB | |
2024-11-28 00:00 |
Quarterly Report
Q3 statement / Q3 financial report 2024
|
English | 517.2 KB | |
2024-11-25 12:00 |
Directors' Dealings
PharmaSGP Holding SE: FUTRUE GmbH, buy
|
English | 7.8 KB | |
2024-11-05 10:07 |
Board/Management Change
CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as …
|
English | 9.2 KB |
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
2024-11-25 | FUTRUE GmbH | Close relation | Buy | None | 12,145,250.00 EUR |
2022-10-05 | MMI Leisure & Capital Management GmbH | Close relation | Buy | None | 125,383.20 EUR |
2022-10-05 | Hillen, Ingo | Board | Buy | None | 1,048.00 EUR |
2022-10-05 | MMI Leisure & Capital Management GmbH | Close relation | Buy | None | 26.60 EUR |
2022-05-30 | Wittig, Dr. Thomas | Supervisory board | Buy | None | 138,953.80 EUR |
2022-05-30 | Schröter, Jasmin | Close relation | Buy | None | 119,660.00 EUR |
2022-05-30 | Simon-Schröter, Dr. Wolfram | Other | Buy | None | 10,040.00 EUR |
2022-04-25 | FUTRUE GmbH | Close relation | Buy | None | 208,180.53 EUR |
2022-04-25 | MMI Leisure & Capital Management GmbH | Close relation | Sell | None | 197,193.60 EUR |
2022-04-25 | Bloching, Prof. Dr. Micha | Supervisory board | Sell | None | 171,825.00 EUR |
Peer Companies
Company | Country | Ticker | View | |
---|---|---|---|---|
![]() |
Valneva SE | France | VLA | |
![]() |
VENTURE LIFE GROUP PLC | United Kingdom | VLG | |
![]() |
Vetoquinol SA | France | VETO | |
![]() |
Vicore Pharma Holding | Sweden | VICO | |
|
Vifor Pharma AG | Switzerland | VIFN | |
![]() |
Vimian Group AB | Sweden | VIMIAN | |
![]() |
Virbac | France | FR000 | |
|
Vistin Pharma | Norway | VISTN | |
![]() |
Vivesto | Sweden | VIVE | |
![]() |
Xlife Sciences AG | Switzerland | XLS |